AN2 Therapeutics grants options and RSUs to two new hires
AN2 Therapeutics reports inducement grants to two newly hired employees, including options on 10,565 shares and 5,283 RSUs, per Nasdaq rule 5635(c)(4).
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
AN2 Therapeutics, a clinical-stage biopharma company, said its compensation committee approved inducement equity awards for two newly hired employees on October 19, 2026. According to TradingView, which republished the Business Wire release, the package covers options on 10,565 common shares and 5,283 restricted stock units.
The options carry an exercise price of $3.37, equal to the Nasdaq Global Market closing price on October 19. One quarter of the options vests after one year, with the rest vesting monthly afterward. The RSUs vest annually over four years, subject to continued service.
The grants were made under the company's 2026 Employment Inducement Award Plan in line with Nasdaq Listing Rule 5635(c)(4).
why it matters
The filing is routine and small in size, so it is unlikely to move the stock or the broader biotech sector. It mainly matters to investors tracking compensation structure and potential share dilution.
tags
instruments
sources
- AN2 Therapeutics, Inc. Reports Inducement Grants Under Listing Rule 5635(c)(4) — TradingView, 23 October 2026 at 21:00 UTC
- AN2 Therapeutics, Inc. Reports Inducement Grants Under Listing Rule 5635(C)(4) — Reuters, 23 October 2026 at 22:20 UTC
- Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) — Reuters, 23 October 2026 at 22:17 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗